Innoviva Q3 2026: IST Sales Jump 45%, Net Loss Hits $73.9M

Innoviva, Inc. (NASDAQ: INVA) reported third quarter 2026 results on Nov 4, 2026, posting total revenue of $106.1 million and a net loss of $73.9 million, or $1.03 per basic share. The loss stemmed from a $139.5 million unfavorable swing in the fair value of equity and long-term investments, not from operations. Innoviva Specialty Therapeutics generated $43.3 million in U.S. net product sales, up 45% year over year, while gross royalty revenue from GSK held at $58.1 million.

Context — why the Innoviva Q3 2026 earnings split matters now

Innoviva's structure forces readers to look at two businesses at once. One is a royalty stream tied to GSK respiratory products, the other is a commercial specialty therapeutics platform the company has been scaling. The report frames the royalty portfolio as durable and the IST platform as the growth engine.

The year-over-year comparison shows the tension. Total revenue slipped 1.6%, from $107.8 million in the third quarter of 2025 to $106.1 million. U.S. net product sales grew sharply, but that gain was partly offset by lower royalty revenue and by fluctuations in the timing of inventory sales to ex-U.S. partners.

Operating income moved the other way. Income from operations rose 21.9% to $42.2 million, from $34.6 million a year earlier. The company attributed the increase to higher U.S. net product sales, partly offset by higher operating expenses tied to expanding commercial activity.

The swing factor sat below the operating line. Changes in fair values of equity method investments were a negative $97.6 million for the quarter, against a positive $30.8 million a year earlier. A separate line for equity and long-term investments was a negative $41.9 million. The company tied the bulk of the markdown to a decline in the stock price of Armata Pharmaceuticals at quarter-end.

That accounting move, not commercial performance, flipped the bottom line. Innoviva reported net income of $89.9 million in the third quarter of 2025; this quarter it reported a net loss of $73.9 million.

Data — what the Innoviva Q3 2026 numbers show

U.S. net product sales of $43.3 million compared with $29.9 million in the same quarter of 2025. Within that, the company reported $23.1 million from GIAPREZA, $16.1 million from XACDURO, and $3.4 million from XERAVA. Ex-U.S. sales added $6.1 million, bringing total net product sales to $49.4 million.

Gross royalty revenue from GSK was $58.1 million, flat against the prior-year quarter. Net royalty revenue, after amortization of capitalized fees, was $54.7 million, down from $59.9 million.

Metric	Q3 2026	Q3 2025
Total revenue	$106.1M	$107.8M
U.S. net product sales	$43.3M	$29.9M
Income from operations	$42.2M	$34.6M
Net income (loss)	-$73.9M	$89.9M
Basic EPS	-$1.03	$1.30

Cash and cash equivalents totaled $581.4 million, up from $550.9 million at Dec 31, 2025. Royalty and product sale receivables were $102.1 million. Strategic healthcare investments were valued at $535.5 million, split into $323.7 million in Armata Pharmaceuticals, $179.9 million in other strategic equity and convertible debt investments, and $31.9 million held by ISP Fund.

For the nine months ended Sept 30, 2026, total revenue was $323.7 million against $296.7 million a year earlier. Nine-month net income was $29.3 million, or $0.40 per basic share, compared with $107.0 million, or $1.65 per basic share.

Analysis — what the Innoviva earnings mean for healthcare investors

The report's own framing points to operating use as the mechanism. Management said it expects operating use, supported by fiscal discipline, to strengthen profitability as revenues grow. That is a forward-looking statement, not a result.

The cost line already reflects the build. Selling, general and administrative expense rose to $37.0 million from $27.3 million, while research and development fell to $5.2 million from $13.7 million. The mix shift shows spending moving from development toward commercialization.

Armata exposure is the acknowledged weak point. A single portfolio holding, marked at $323.7 million, drove most of the quarterly fair-value loss through equity method accounting. That concentration means Innoviva's reported net income can diverge sharply from operating performance in any given quarter, which complicates simple earnings comparisons.

The counter-argument: the operating business improved. Income from operations rose 21.9% even as total revenue declined, and gross profit rose to $84.4 million from $75.5 million. Cost of products sold fell to $15.0 million from $25.6 million, which the company attributes partly to amortization of inventory fair value adjustments.

Positioning follows the split. Royalty and cash-flow investors watch the GSK line and the buyback. Growth investors watch IST's commercial trajectory and the $150 million U.S. net product sales target. The Armata mark is the swing factor neither group controls.

Outlook — what to watch next for INVA

The company reiterated 2026 guidance of at least $150 million in U.S. net product sales for IST. U.S. net product sales reached $43.3 million in the quarter, so the target depends on fourth-quarter execution.

NUZOLVENCE, described as a first-in-class single-dose oral antibiotic for uncomplicated urogenital gonorrhea, is now commercially available in the U.S. Management said initial efforts focus on market access, distribution, and dispensing infrastructure. The report gives no revenue contribution from the product this quarter.

The $125 million share repurchase program remains open. Innoviva repurchased 1,226,948 shares for $26.3 million in the quarter, and 3,829,116 shares for $82.7 million since inception. That leaves roughly $42.3 million authorized.

The company did not disclose a date for fourth-quarter results or specific Armata-related guidance. The report names no price levels or technical thresholds.

Frequently Asked Questions

Why did Innoviva report a net loss in Q3 2026?

The loss came from below the operating line. Innoviva recorded $139.5 million in net unfavorable changes in the fair value of equity and long-term investments, mainly a decline in Armata Pharmaceuticals' stock price at quarter-end. Income from operations was positive at $42.2 million, up 21.9% year over year. The fair-value swing, not commercial weakness, drove the $73.9 million net loss.

What is Innoviva's 2026 guidance for U.S. net product sales?

Management reiterated guidance of at least $150 million in U.S. net product sales for 2026 under the Innoviva Specialty Therapeutics platform. The company reported $43.3 million in the third quarter, up 45% year over year, and $142.6 million in total net product sales for the first nine months. Hitting the target depends on fourth-quarter commercial performance.

How much of Innoviva's buyback program is left?

Innoviva repurchased 1,226,948 shares for $26.3 million during the third quarter under a $125 million program. Since inception through the end of the quarter, the company had repurchased 3,829,116 shares for $82.7 million. That leaves approximately $42.3 million of authorization remaining. The company said the repurchases reflect confidence in its intrinsic value and long-term outlook.

Bottom Line

Innoviva's operating income rose 21.9% while a $139.5 million Armata-linked fair-value mark turned the quarter into a $73.9 million net loss.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.